Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076285 | 1.00 | SIRT2 (0.49) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| SCHEMBL29357392 | 1.00 | SIRT2 (0.49) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| SCHEMBL10727549 | 0.98 | SIRT2 (0.50) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| Hydrochloric Acid SCHEMBL380911 | 0.98 | SIRT2 (0.49) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| SCHEMBL1842451 | 0.97 | SIRT2 (0.46) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| SCHEMBL29374941 | 0.97 | SIRT2 (0.46) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| SCHEMBL31045803 | 0.97 | SIRT2 (0.51) | SIRT2SIRT1RAB9ASIRT3 | |
| SCHEMBL30070668 | 0.97 | SIRT2 (0.48) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| Hydrochloric Acid SCHEMBL31754825 | 0.96 | SIRT2 (0.46) | SIRT2SIRT1RAB9ATDP1SIRT3 | |
| Hydrochloric Acid SCHEMBL1723683 | 0.96 | SIRT2 (0.46) | SIRT2SIRT1RAB9ATDP1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | SIRT2 3334/4885SIRT1 2581/4885RAB9A 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.